BR112021006298A2 - composições e métodos para estabilizar coelenterazina e análogos e derivados da mesma - Google Patents

composições e métodos para estabilizar coelenterazina e análogos e derivados da mesma

Info

Publication number
BR112021006298A2
BR112021006298A2 BR112021006298A BR112021006298A BR112021006298A2 BR 112021006298 A2 BR112021006298 A2 BR 112021006298A2 BR 112021006298 A BR112021006298 A BR 112021006298A BR 112021006298 A BR112021006298 A BR 112021006298A BR 112021006298 A2 BR112021006298 A2 BR 112021006298A2
Authority
BR
Brazil
Prior art keywords
coelenterazine
analogues
derivatives
stabilizing
compositions
Prior art date
Application number
BR112021006298A
Other languages
English (en)
Inventor
Wood Keith
Dart Melanie
Kirkland Thomas
Machleidt Thomas
Smith Thomas
Original Assignee
Promega Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Promega Corp filed Critical Promega Corp
Publication of BR112021006298A2 publication Critical patent/BR112021006298A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
    • C09K11/02—Use of particular materials as binders, particle coatings or suspension media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0018—Pullulan, i.e. (alpha-1,4)(alpha-1,6)-D-glucan; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K5/00—Use of organic ingredients
    • C08K5/16—Nitrogen-containing compounds
    • C08K5/34—Heterocyclic compounds having nitrogen in the ring
    • C08K5/3442—Heterocyclic compounds having nitrogen in the ring having two nitrogen atoms in the ring
    • C08K5/3462—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L25/00—Compositions of, homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an aromatic carbocyclic ring; Compositions of derivatives of such polymers
    • C08L25/02—Homopolymers or copolymers of hydrocarbons
    • C08L25/04—Homopolymers or copolymers of styrene
    • C08L25/06—Polystyrene
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L33/00—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
    • C08L33/04—Homopolymers or copolymers of esters
    • C08L33/06—Homopolymers or copolymers of esters of esters containing only carbon, hydrogen and oxygen, which oxygen atoms are present only as part of the carboxyl radical
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16—Cyclodextrin; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L71/00—Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
    • C08L71/02—Polyalkylene oxides
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
    • C09K11/06—Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/66—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving luciferase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label

Abstract

composições e métodos para estabilizar coelenterazina e análogos e derivados da mesma. trata-se de composições e métodos para estabilizar coelenterazina e análogos ou derivados da mesma e para melhorar eficácia de reconstituição e solubilidade de coelenterazina e análogos e derivados da mesma.
BR112021006298A 2018-10-03 2019-10-03 composições e métodos para estabilizar coelenterazina e análogos e derivados da mesma BR112021006298A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862740622P 2018-10-03 2018-10-03
US201962805517P 2019-02-14 2019-02-14
PCT/US2019/054501 WO2020072775A2 (en) 2018-10-03 2019-10-03 Compositions and methods for stabilizing coelenterazine and analogs and derivatives thereof

Publications (1)

Publication Number Publication Date
BR112021006298A2 true BR112021006298A2 (pt) 2021-07-06

Family

ID=68296818

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021006298A BR112021006298A2 (pt) 2018-10-03 2019-10-03 composições e métodos para estabilizar coelenterazina e análogos e derivados da mesma

Country Status (11)

Country Link
US (2) US11534504B2 (pt)
EP (2) EP4015644A1 (pt)
JP (1) JP7447101B2 (pt)
KR (1) KR20210072040A (pt)
CN (1) CN112996923A (pt)
AU (1) AU2019355136A1 (pt)
BR (1) BR112021006298A2 (pt)
CA (1) CA3114424A1 (pt)
IL (1) IL281844A (pt)
SG (1) SG11202103289SA (pt)
WO (1) WO2020072775A2 (pt)

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7268229B2 (en) 2001-11-02 2007-09-11 Promega Corporation Compounds to co-localize luminophores with luminescent proteins
US7659078B1 (en) 2002-07-17 2010-02-09 University Of Kentucky Research Foundation Method and kit for determination of prostacyclin in plasma
EP2778234B1 (en) 2005-05-31 2017-09-27 Promega Corporation Luminogenic and fluorogenic compounds and methods to detect molecules or conditions
WO2008118445A1 (en) 2007-03-26 2008-10-02 Promega Corporation Methods to quench light from optical reactions
GB0905410D0 (en) 2009-03-28 2009-05-13 Gentronix Ltd Genotoxicity testing
JP6038649B2 (ja) 2009-05-01 2016-12-07 プロメガ コーポレイションＰｒｏｍｅｇａ Ｃｏｒｐｏｒａｔｉｏｎ 増大した光出力を有する合成オプロフォルスルシフェラーゼ
US8847872B2 (en) 2010-07-07 2014-09-30 Himax Display, Inc. Display for driving a pixel circuitry with positive and negative polarities during a frame period and pixel circuitry
SG10202103336SA (en) 2010-11-02 2021-04-29 Promega Corp Novel coelenterazine substrates and methods of use
WO2012061477A1 (en) 2010-11-02 2012-05-10 Promega Corporation Coelenterazine derivatives and methods of using same
US20130272966A1 (en) 2012-04-12 2013-10-17 The Board Of Trustees Of The Leland Stanford Junior University Ret2ir conjugates, ret2ir conjugate systems and methods of use thereof
AU2013204332B2 (en) * 2012-04-16 2015-07-16 Commonwealth Scientific And Industrial Research Organisation Methods and systems for detecting an analyte or classifying a sample
EP2893327B1 (en) * 2012-09-01 2020-11-04 Prolume, Ltd. Coelenterazine compounds and methods of use
EP2900833B1 (en) 2012-09-26 2018-05-30 Promega Corporation Real-time monitoring
SG10201601929YA (en) 2013-03-15 2016-04-28 Promega Corp Activation Of Bioluminescence By Structural Complementation
AU2013394649B2 (en) * 2013-07-18 2020-07-16 Ecole Polytechnique Federale De Lausanne (Epfl) Means and methods for bioluminescence resonance energy transfer (BRET) analysis in a biological sample
JP6588917B2 (ja) 2014-01-29 2019-10-09 プロメガ コーポレイションＰｒｏｍｅｇａ Ｃｏｒｐｏｒａｔｉｏｎ 生細胞への適用のためのプロ基質
EP2930497A1 (en) 2014-04-07 2015-10-14 Institut Pasteur Enzyme-independent photon emission
SG11201609382WA (en) 2014-05-23 2016-12-29 Promega Corp Compositions and methods for stabilizing luminogenic substrates
JP6688499B2 (ja) 2014-10-27 2020-04-28 国立大学法人 鹿児島大学 安定性が増加したウミシイタケ（Ｒｅｎｉｌｌａｒｅｎｉｆｏｒｍｉｓ）由来ルシフェラーゼ変異体
EP3259365B1 (en) 2015-02-16 2020-04-01 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Sensors, methods and kits for detecting nicotinamide adenine dinucleotides
US9908918B2 (en) 2015-06-30 2018-03-06 The Board Of Trustees Of The Leland Stanford Junior University Cyan-excitable orange-red fluorescent proteins and bioluminescent resonance energy transfer systems
EP4086261A1 (en) 2016-02-15 2022-11-09 Promega Corporation Process for the preparation of coelenterazine analogues
WO2018022865A1 (en) 2016-07-28 2018-02-01 Promega Corporation Coelenterazine analogues
JP6978492B2 (ja) 2016-09-09 2021-12-08 プロメガ コーポレイションPromega Corporation 二重保護されたプロセレンテラジン基質
EP3535270B1 (en) 2016-11-01 2022-07-27 Promega Corporation Coelenterazine analogues tethered to energy acceptors
EP4279490A3 (en) 2016-12-01 2024-04-10 Promega Corporation Cell impermeable coelenterazine analogues
US11959121B2 (en) 2017-05-30 2024-04-16 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Sensors, methods and kits for detecting NADPH based on resonance energy transfer
KR102660777B1 (ko) 2017-08-08 2024-04-24 커먼웰쓰 사이언티픽 앤드 인더스트리얼 리서치 오가니제이션 탄수화물 센서
US20200393450A1 (en) 2017-08-25 2020-12-17 Technische Universiteit Eindhoven Detection device for bioluminescent detection of biomarkers from a biological fluid sample using luminescent sensing proteins
US11655247B2 (en) 2018-05-01 2023-05-23 Promega Corporation Nanoluc suicide substrates
US20200085990A1 (en) 2018-06-29 2020-03-19 International Paper Company Chemiluminescent wetness indicator for absorbent products
US11691976B2 (en) 2018-08-23 2023-07-04 Promega Corporation Coelenterazine analogues

Also Published As

Publication number Publication date
CA3114424A1 (en) 2020-04-09
JP7447101B2 (ja) 2024-03-11
WO2020072775A3 (en) 2020-07-23
CN112996923A (zh) 2021-06-18
EP3861128A2 (en) 2021-08-11
US20230092932A1 (en) 2023-03-23
US11534504B2 (en) 2022-12-27
KR20210072040A (ko) 2021-06-16
WO2020072775A2 (en) 2020-04-09
SG11202103289SA (en) 2021-04-29
IL281844A (en) 2021-05-31
JP2022512611A (ja) 2022-02-07
US20200109146A1 (en) 2020-04-09
EP4015644A1 (en) 2022-06-22
AU2019355136A1 (en) 2021-04-29

Similar Documents

Publication Publication Date Title
CO2019013010A2 (es) Inhibidores de kras g12c y métodos para su uso
CY1124959T1 (el) Αναστολεις λυσινης ειδικης απομεθυλασης-1
CY1124011T1 (el) Συνθεσεις γλυκοπεπτιδιου
CO2020009861A2 (es) Inhibidores pd-1/pd-l1
CY1120361T1 (el) Αναστολεις 2,3-διοξυγενασης ινδολαμινης (ido)
PH12021500014A1 (en) Fused ring compounds
UY37870A (es) Inhibidores de kras g12c y métodos para utilizarlos campo de la invención
CY1124891T1 (el) Pd-1/pd-l1 αναστολεις
CO2019000386A2 (es) Compuestos heterocíclicos como inmunomoduladores
CY1123626T1 (el) Ετεροκυκλικοι αναστολεις πρωτεϊνικης κινασης
CO2018007528A2 (es) Compuestos heterocíclicos como inmunomoduladores
CL2017002494A1 (es) Inhibidores de indolamina-2, 3- dioxigenasa para el tratamiento de cancer
EA201790078A1 (ru) Ингибиторы mnk и связанные с ними способы
EA201690027A1 (ru) Ингибиторы ido
EA201692091A1 (ru) Хиноксалиновые соединения и их применение
BR112021020285A2 (pt) Métodos e composições para degradação de proteína alvejada
EA201792580A1 (ru) Ингибиторы ido
CO2018004572A2 (es) Inhibidores de calicreína plasmática humana
CY1124967T1 (el) Παραγωγα αμινοπυριδινης και χρηση αυτων ως εκλεκτικοι αναστολεις alk-2
CY1123722T1 (el) Ενεσιμα φαρμακευτικα σκευασματα λεφαμουλινης
EA202091337A1 (ru) Ингибиторы гистонацетилтрансфераз семейства myst
EA202191192A1 (ru) Кристаллические соли ингибитора плазменного калликреина
BR112021006298A2 (pt) composições e métodos para estabilizar coelenterazina e análogos e derivados da mesma
EA201890847A1 (ru) Композиции и способы ингибирования бета-лактамазы
EA201991595A1 (ru) Активатор nrf2